In vitro treatment of MMECs with thalidomide significantly reduces the expression and release of angiogenic cytokines, such as VEGF, FGF-2, and HGF [80], implying a modulation of cytokine/growth factors in the BM milieu of thalidomide-treated MM patients. The gene discussed is FGF2; the disease is Miyoshi myopathy.